Idiopathic Pulmonary Fibrosis clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-14
What changed in the last 30 days
20 trials changed in the last 30 days: 1 stopped, 3 with notable changes, 16 with minor changes only.
- Minor: OCEAN-1 · Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets Trial sites expanded: 22 → 32 locations
- Minor: OCEAN-2 · Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets Trial sites expanded: 4 → 16 locations
- Minor: BI 3810477 Helps · Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment Trial sites expanded: 37 → 42 locations
- Notable: PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort Start date pushed from Mar 2015 to Jun 1, 2015
- Minor: IPF/ILD-PRO · Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry Trial sites expanded: 47 → 50 locations
- Minor: RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses Primary completion pushed from Nov 2026 to Apr 2027
-
Minor: 2 trials marked Unknown by the registry's verification sweep Changed
- Minor: D Vitamin and Alveolar Macrophages in Idiopathic Pulmonal Fibrosis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: PIPE 791 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 105 → 108 locations
- Minor: SAIL · Subjects Who Received an Avalyn Inhaled Antifibrotic Agent Trial sites expanded: 85 → 92 locations
- Minor: ARGiNAUT · AZD8965 · IPF Trial sites expanded: 195 → 198 locations
- Minor: SURPASS-IPF · LYT-100 (Deupirfenidone) Compared to Pirfenidone · Idiopathic Pulmonary Fibrosis (IPF) Trial sites expanded: 10 → 18 locations
- Notable: Repeated Doses of Inhaled CHF10073 · Idiopathic Pulmonary Fibrosis Primary endpoint(s) modified
- Minor: OPTIMIZE-ILD-2 · Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial Enrollment closed, study ongoing
- Stopped: Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for IPF Trial terminated
- Notable: Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF Recruitment opened
- Minor: ZAPPHIRE · Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) · Idiopathic Pulmonary Fibrosis Trial sites expanded: 3 → 19 locations
- Minor: LTI-03 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 36 → 48 locations
- Minor: WISPer · MTX-463 · Idiopathic Pulmonary Fibrosis (IPF) Enrollment closed, study ongoing
- Minor: AURA-IPF · AP02 (Nintedanib Solution) in IPF Trial sites expanded: 24 → 49 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-12 | NCT07933133 A Multicenter, Randomized, Blinded, Placebo- and Active-Controlled Phase II Study to… | CSPC-NBP Pharmaceutical Co., Ltd. new | Phase 2 |
| 2026-11-10 | NCT07929948 A Phase Ⅱa Study of ND-003 Tablets in Patients With Idiopathic Pulmonary Fibrosis | Shenzhen NewDEL Biotech, Co., Ltd new | Phase 2 |
| 2026-11-05 | NCT07919015 Real-world Study of Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis and… | Avraham Unterman new | |
| 2026-11-02 | NCT07909655 A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis | Shanghai Huaota Biopharmaceutical Co., Ltd. new | Phase 2 |
| 2026-10-09 | NCT07869147 Study of ORJ-001 for the Treatment of IPF | Oorja Bio, Inc. new | Phase 2 |
| 2026-10-07 | NCT07862634 A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis | Agomab Spain S.L.U. new | Phase 2 |
Active trials by phase
| Early Phase 1 | 4 | |
| Phase 1 | 14 | |
| Phase 1/2 | 2 | |
| Phase 2 | 44 | |
| Phase 2/3 | 1 | |
| Phase 3 | 16 |
Not charted: 70 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Assiut University (5) · Boehringer Ingelheim (3) · Bristol-Myers Squibb (3) · Haisco Pharmaceutical Group Co., Ltd. (3) · Henan University of Traditional Chinese Medicine (3) · Hospital de Granollers (3) · Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (3) · Istituto Clinico Humanitas (3) · University of Colorado, Denver (3) · University of Virginia (3)
Get alerts when Idiopathic Pulmonary Fibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.